3432 results about "Gastroenterology" patented technology

The disclosure provides methods for treating treatment-resistant depression a subject in need thereof comprising administering to the subject two or more doses of psilocybin. The methods described herein may be used to treat subjects both responsive and unresponsive to a first dose of psilocybin

Systems and methods are disclosed for diagnosis, risk assessment, and / or virtual treatment assessment of visceral ischemia and related disorders. One method includes receiving a patient-specific anatomic model of a patient's visceral vasculature, including visceral vasculature of the patient's visceral organs and bowel; determining a location in the patient-specific anatomic model of the patient's visceral vasculature; determining, for the location in the patient-specific anatomic model, a blood flow characteristic of blood flow through the location in the patient-specific anatomic model of the patient's visceral vasculature; determining a tissue region of the patient's bowel proximate the location in the patient-specific anatomic model of the patient's visceral vasculature; and generating an assessment of blood supply adequacy to the tissue region of the patient's bowel or generating a risk score for risk of disease for the patient's bowel, based on the determined blood flow characteristic and an expected blood flow characteristic associated with the tissue region of the patient's bowel.

Systems and methods are disclosed for diagnosis, risk assessment, and / or virtual treatment assessment of visceral ischemia and related disorders. One method includes receiving a patient-specific anatomic model of a patient's visceral vasculature, including visceral vasculature of the patient's visceral organs and bowel; determining a location in the patient-specific anatomic model of the patient's visceral vasculature; determining, for the location in the patient-specific anatomic model, a blood flow characteristic of blood flow through the location in the patient-specific anatomic model of the patient's visceral vasculature; determining a tissue region of the patient's bowel proximate the location in the patient-specific anatomic model of the patient's visceral vasculature; and generating an assessment of blood supply adequacy to the tissue region of the patient's bowel based on the determined blood flow characteristic and an expected blood flow characteristic associated with the tissue region of the patient's bowel.

This disclosure provides methods of treating cystic fibrosis or a CFTR-mediated disease comprising administering Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing. The disclosure also provides pharmaceutical compositions comprising Compound I, a deuterated derivative thereof, or a pharmaceutically acceptable salt of any of the foregoing, and optionally comprising one or more additional CFTR-modulating agents.

This specification describes systems and methods for performing endoscopy, obtaining medical images for inflammatory bowel disease (IBD) and scoring severity of IBD in patients. The methods and systems are configured for using machine learning to determine measurements of various characteristics related to IBD. The methods and systems may also obtain and incorporate electronic health data of patients along with endoscopic data to use for scoring purposes.

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt thereof) that degrade and / or otherwise modulate (e.g., inhibit) NIMA Related Kinase 7 (NEK7). Said chemical entities are useful, e.g., for treating a subject (e.g., a human subject) having one or more disorders or diseases associated with NLRP3 inflammasome activation. Said disorders or diseases include but are not limited to, autoinflammatory and autoimmune disorders (e.g., gout, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease), cardiovascular and metabolic disorders (eg. pericarditis, atherosclerosis, Type 2 diabetes, obesity, and metabolic syndrome), fibrotic disorders (e.g. interstitial lung disease, chronic kidney disease), hematology (eg. anemia of inflammation) and eye disorders (eg. macular degeneration). In embodiments, and while not wishing to be bound by theory, it is believed that the chemical entities described herein directly target (e.g., directly bind to) NEK7, thereby altering (e.g., attenuating) the inflammatory response modulated by the NLRP3 inflammasome. This disclosure also features compositions containing the same as well as methods of using and making the same.

The invention discloses a strain of bifidobacterium animalis dipro-60 and a preparation method thereof. The invention further discloses a preparation, and the preparation contains the bifidobacterium animalis dipro-60. The bifidobacterium animalis dipro-60 used in the invention has the ability of producing bile salt hydrolase BSH, the ability of reducing cholesterol, the ability of inhibiting helicobacter pylori and the ability of reducing inflammatory factor TNF-alpha; further animal experiments show that the dipro-60 can improve lipid metabolism related diseases, can significantly reduce weight gain of obese mice induced by high fat, significantly reduce the liver weight of the obese mice, reduce the content of triglyceride and blood sugar in blood, improve intestinal barriers and improve the lipid metabolism related diseases, and the dipro-60 can improve the lipid metabolism related diseases. Liver lipid accumulation caused by obesity or hyperlipidemia is improved, and bone loss caused by obesity or hyperlipidemia is improved.

The present disclosure provides compositions and methods for treating a disease or condition in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a composition comprising a plurality of particles comprising at least one therapeutic biologic suspended in a pharmaceutically acceptable liquid carrier.

To provide formulations for treatment of hypertension, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pains, asthma, pulmonary arterial hypertension, and chronic obstructive pulmonary disease.SOLUTION: The invention provides a chemical formulation for use in a method of treating a disease, the method comprising: inserting a delivery catheter into a vascular lumen adjacent to nerves, where the vascular lumen includes a pulmonary artery; infusing the chemical formulation into the vascular lumen through the delivery catheter, where the amount of the chemical formulation is an amount effective to injure or damage the nerves and provide benefits in alleviating the symptoms of the disease; and withdrawing the delivery catheter from the blood vessel. The chemical formulation is at least one of 10-100 wt.% of ethanol, and 1-100 wt.% of acetic acid. The disease includes pulmonary arterial hypertension.SELECTED DRAWING: None

Provided herein are variant α4β7 integrin antibodies and methods of use.

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-COV-2. Lung function stabilizes or is improved as a result of treatment.

An apparatus and method for an oral nicotine dispensing system. The apparatus includes storing a plurality of a pods in a magazine within a body, receiving a fingerprint scan from a user via a fingerprint scanner coupled to the body, authenticating the fingerprint scan, de-activating a locking mechanism to allow access to at least a pod upon successful authentication of the fingerprint scan, and dispensing, using at least a drive mechanism, the at least a pod from the magazine through an opening of the body.

The present disclosure relates to a compound for use in treating chronic obstructive pulmonary disease (COPD) in a patient, which compound is ensifentrine or a pharmaceutically acceptable salt thereof, wherein the patient has a blood eosinophil count of <300 cells / μL, <150 cells / μL, or <100 cells / μL.

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-CoV-2. Lung function stabilizes or is improved as a result of treatment.

Disclosed herein are methods that aid in the diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild or moderate to severe traumatic brain injury (TBI), using an early biomarker, ubiquitin carboxy-terminal hydrolase L1 (UCH-L1). Also disclosed here are methods that aid in determining whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting levels and changes in levels of UCH-L1 in one or more samples taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.

The invention relates to the field of biomedical materials, and particularly discloses a manganese dioxide nano-enzyme for treating inflammatory bowel disease as well as a preparation method and application of the manganese dioxide nano-enzyme. The preparation method of the manganese dioxide nano-enzyme comprises the following steps: uniformly mixing an organic solution containing manganese nitrate hexahydrate with a montmorillonite aqueous solution to obtain a mixed reaction solution; the pH value of the mixed reaction solution is adjusted to be under the alkaline condition through alkali liquor, a synthetic reaction is carried out, then centrifugation and washing are carried out, the montmorillonite-loaded manganese dioxide nano-enzyme is obtained, and the manganese dioxide nano-enzyme is of a lamellar structure with the length being 20-400 nm. The manganese dioxide nano enzyme has excellent activity similar to superoxide dismutase, catalase and glutathione peroxidase; meanwhile, the compound also has the capability of removing various free radicals such as DPPH and ABTS, can be used for treating the inflammatory bowel disease, and has a wide application prospect.

The invention relates to a new non-invasive quantitative test making it possible to detect liver fibrosis in type-2diabetes using non-invasive tests that are sex-specific.

The present disclosure provides a method of treating a fatty liver disease (e.g., non-alcoholic steatohepatitis (NASH)) in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof. The present disclosure also provides a method of improving liver fibrosis in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof.

The preservation number of the bacterial strain is CGMCC (China General Microbiological Culture Collection Center) NO.33629, the preservation date of the bacterial strain is February 24, 2025, the preservation classification of the bacterial strain is Lactobacillus sakei, and the preservation unit of the bacterial strain is China General Microbiological Culture Collection Center. The strain provided by the invention can reduce the concentration of blood uric acid, relieve kidney inflammation caused by hyperuricemia, improve the protein level of a kidney uric acid excretion channel and reduce the expression level of uric acid resorption protein.

The invention relates to a new non-invasive quantitative test making it possible to detect liver Non-Alcoholic Steatotic Hepatitis (NASH) in type-2diabetes and help identify subjects at risk of NASH using non-invasive tests that are sex-specific.

This disclosure relates generally to methods for treating an inflammatory bowel disease ("IBD", e.g., Crohn's disease or ulcerative colitis) in a patient. More particularly, this disclosure relates to methods for selecting a therapy for treating a patient suffering from an IBD. In embodiments, the foregoing can also be used to assess the severity of the IBD. The predictive aspects of said methods can facilitate and expedite the identification and stratification of IBD patient populations that are responsive to treatment with a RIPK2 inhibitor. The foregoing methods can further include treating the IBD by administering a RIPK2 inhibitor to the patient.

The invention relates to a liver transplantation post-operation nursing recommendation method and system based on an NNN link system, and the method comprises the steps: carrying out the construction of a knowledge graph based on the related data of a liver transplantation recipient post-operation NNN link, and constructing a corresponding liver transplantation post-operation nursing knowledge graph; and putting the liver transplantation postoperative nursing knowledge graph into clinical application, predicting an NNN nursing decision scheme matched with liver transplantation symptom information according to the liver transplantation symptom information of a clinical liver transplantation recipient, and executing the NNN nursing decision scheme on a patient. According to the method, an auxiliary decision-making system can be generated, medical staff are helped to reasonably set an outcome target for a liver transplantation recipient and formulate targeted nursing measures, the nursing efficiency is improved, and time and energy consumed by medical care decision making are saved. According to the invention, nurses can be guided to accurately identify and determine existing and potential health problems of liver transplantation recipients. Meanwhile, by introducing an NNN link system, systematized, standardized and intelligent management of postoperative care of liver transplantation recipients is realized.

25HC3S choline and crystalline 25HC3S choline are described herein. Pharmaceutical formulations of 25HC3S choline such as with crystalline 25HC3S choline and methods of treating or preventing disease with same such as hypercholesterolemia, hypertriglyceridemia, and conditions related to fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis) are further disclosed herein. Methods for preparing 25HC3S, including crystalline 25HC3S choline, are also provided.

The invention relates to a new non-invasive quantitative test making it possible to detect liver steatosis in type-2diabetes and help identify subjects at risk of non-alcoholic fatty liver disease (NAFLD) using non-invasive tests that are sex-specific.

The present specification provides methods and compositions for treating fibrosis, particularly pulmonary fibrosis. The pulmonary fibrosis may be idiopathic or arise following an infection of the lung. The lung infection can be by SARS-COV-2. Lung function stabilizes or is improved as a result of treatment.

The invention discloses an application of a streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet in preparation of a product for treating adenoid body inflammation. The preservation number of the streptococcus salivarius subsp. Thermophilus Biohalo 23 is DSM34540; the streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet disclosed by the invention can be used for relieving the disease symptom of adenoid body inflammation and reducing the incidence rate of adenoid body inflammation, so that the streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet disclosed by the invention has a remarkable curative effect on adenoid body inflammation, and particularly, through clinical tests, the streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet has a remarkable curative effect on adenoid body inflammation. The streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet disclosed by the invention can be used for remarkably improving symptoms such as tachypnea, mouth breathing, snoring, cough, nasal obstruction, hearing loss and the like, and also can be used for reducing the incidence rate of adenoid body inflammation, so that the streptococcus salivarius subsp. Thermophilus Biohalo 23 tablet disclosed by the invention can be used for treating the adenoid body inflammation.

To provide an adiponectin enhancer and an oral composition for enhancing adiponectin, having the effect of enhancing adiponectin.SOLUTION: An adiponectin enhancer comprises plasmalogen as an active ingredient.SELECTED DRAWING: Figure 1

The application relates to methods of diagnosis of status epilepticus (SE) or new onset refractory status epilepticus (NORSE), as well as determining the likelihood of mortality associated with SE and / or NORSE, based on mammalian gastrointestinal (GI) microbiota. The application further relates to the treatment or prevention of SE and / or NORSE, or mortality associated with these conditions via use of probiotics, prebiotics, compounds and / or compositions for modulating the GI microbiota.

Stable and bioavailable formulations and dosage forms comprising a dispersion (e.g., spray-dried dispersion) of solid amorphous 6-(cyclopropancamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-N-(methyl-d3)pyridazine-3-carboxamide (Formula (I): BMS-986165) in a solid polymer matrix are provided for the treatment of auto-immune and auto-inflammatory diseases such as an inflammatory bowel disease (IBD) and psoriasis.

The present disclosure provides a method of treating a fatty liver disease (e.g., non-alcoholic steatohepatitis (NASH)) in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof. The present disclosure also provides a method of improving liver fibrosis in a human subject (e.g., an adult human subject) in need of such treatment (e.g., NASH / improving liver fibrosis) with 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile (resmetirom) or a pharmaceutically acceptable salt thereof.